It’s been a few years since I last cast an eye over Novocure (NASDAQ: NVCR). So I was surprised to see how hard this growth stock (once a Nasdaq darling) has fallen. From a high of $221 in the summer of 2021, it’s now trading for just $17.
That’s a wealth-shredding 92% drop over three years!
Is this fallen star now a bargain hiding in plain sight? Or is this one to avoid? Let’s dig into the details.
What does it do?
Novocure is a medical device company specialising in a unique cancer treatment called Tumour Treating Fields (TTFields). This non-invasive therapy uses electric fields to disrupt cancer cell division, slowing the spread of tumours.
The wearable device primarily targets glioblastoma, a particularly aggressive type of brain cancer. The patches on the scalp deliver electric fields and are connected to a portable device, often carried like a backpack, allowing continuous cancer treatment while maintaining mobility.
At the end of June, there were 3,963 active patients using TTFields therapy, an 11% increase from the previous year.
Mixed results
I was first attracted to the share a few years ago when I heard the firm’s proprietary technology being called the “fourth modality of cancer treatment” (along with surgery, chemotherapy, and radiation).
The hope was that its technology would become a standard treatment for several types of cancer. However, while Novocure has expanded its research to include non-small cell lung cancer, pancreatic cancer, and ovarian cancer, it’s had mixed results so far.
Last year, its phase 3 trial of TTFields in patients with a type of ovarian cancer failed to meet its primary endpoint. On the plus side, it announced earlier this year that its Phase 3 METIS trial, involving patients with lung cancer that had spread to the brain, did meet its primary endpoint. Final results are pending.
Looking forward, a lot will hinge on data due later this year from its phase 3 PANOVA-3 clinical trial in advanced pancreatic cancer. If that is successful, it could open up a significant growth opportunity and be a big catalyst for the stock.
Of course, there’s also a risk these results could disappoint and heap further pressure on the share price.
Sluggish growth and zero profits
The company’s revenue growth has stalled in recent years. And while brokers see a bit of growth in the next couple of years, it isn’t anything to get overly excited about.
Revenue
2022
$538m
2023
$509m
2024
$580m (forecast)
2025
$616m (forecast)
Meanwhile, the firm reported a net loss of $207m last year. And Wall Street has a $150m loss pencilled in for each of the next two years.
That said, the company isn’t in any danger of going under. At the end of June, its cash and short-term investments totalled $951m. But the losses do add risk to the investment case here.
My move
Novocure appears close to expanding its TTFields technology to several cancer types and this could significantly increase its addressable market.
Plus, the stock is trading on a price-to-sales (P/S) ratio of around 3.5. Not obvious bargain territory perhaps, but a lot cheaper than 2021 when the P/S multiple was 14.5.
This share could be set for a big turnaround at some point. So I’m going to keep it on my watchlist while I wait for the company’s upcoming clinical trial results.
The post After a 92% share price crash, is this a bargain basement growth stock? appeared first on The Motley Fool UK.
Should you buy Novocure now?
Don’t make any big decisions yet.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.
And he believes they could bring spectacular returns over the next decade.
Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows…
When such enormous changes hit a big industry, informed investors can potentially get rich.
So, with his new report, Mark’s aiming to put more investors in this enviable position.
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
More reading
Here’s why I think the Vodafone share price could be undervaluing the company by 50%!
Down 23% in 2024! I think I’ve just bagged myself a FTSE 100 bargain
1 FTSE 100 stock I’d buy today to aim for a million
With IAG’s share price down 11%, is it too cheap now for me to ignore?
£11,000 in this 9.4%-yielding FTSE 250 gem could make me £17,158 a year in dividend income over time!
Ben McPoland has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
